Catalent Continues to Expand Global Softgel Drug Delivery Capabilities by Acquiring 100% of R.P. Scherer, Eberbach, Germany
February 29, 2012
SOMERSET, N.J.--(EON: Enhanced Online News)--Catalent Pharma Solutions, a leading global drug delivery technology company, today announced it has completed the acquisition, from Gelita AG, of the remaining 49% minority interest in the R.P. Scherer GmbH & Co. KG, Eberbach, Germany business ("R.P. Scherer Eberbach"). After 60 years of joint partnership, Catalent and Gelita agreed that the R.P. Scherer Eberbach business will be better able to serve the growing European pharmaceutical and consumer health softgel market with R.P. Scherer fully integrated into Catalent. Under full Catalent ownership, customers will have access to a wider range of drug development and delivery technologies/services, and a global supply chain network.
R.P. Scherer Corporation (including the Eberbach joint venture) was founded by the inventor of the rotary die production process for softgel capsules and was sold to Cardinal Health PTS, which is now Catalent Pharma Solutions. Catalent and R.P. Scherer Eberbach have a long heritage of experience, know-how and recognized expertise in softgel formulation and operations.
"We are proud of the strong Catalent and R.P. Scherer Eberbach legacy and are very excited about the future of softgel innovation as an important part of the development, delivery and market supply of pharmaceutical and nutraceutical products. This acquisition comes on the heels of on-going extensive investments that Catalent is making in its softgel facilities in Buenos Aires, Argentina; Aprilia, Italy; and St. Petersburg, Florida; and other investments in advanced drug delivery technologies in Germany and the US," said David Heyens, President of Catalent's Softgel Business.
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 9,400 people at 29 facilities worldwide and in fiscal year 2011 generated more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, NJ. For more information, visit www.catalent.com.
more products. better treatments. reliably supplied.™